Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01331018
Other study ID # 2097.00
Secondary ID NCI-2011-00202RG
Status Terminated
Phase Phase 1
First received
Last updated
Start date February 22, 2012
Est. completion date February 15, 2024

Study information

Verified date May 2024
Source Fred Hutchinson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with FA.


Description:

OUTLINE: STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim subcutaneously (SC) twice daily (BID) for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC once daily (QD) on days 4-6 of mobilization. Peripheral blood stem cell (PBSC) count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days. BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells. REINFUSION: Patients receive methylprednisolone intravenously (IV) or prednisone orally (PO) on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0. After completion of study treatment, patients are followed up periodically for 15 years.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date February 15, 2024
Est. primary completion date February 15, 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years and older
Eligibility Inclusion Criteria: - FA demonstrated by a positive test for increased sensitivity to chromosomal breakage with mitomycin C or diepoxybutane performed by a Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) approved laboratory - FA complementation group A as determined by somatic cell hybrids, molecular characterization, western blot analysis, acquisition of mitomycin C resistance after in vitro lentiviral transduction with a vector bearing the complementary deoxyribonucleic acid (cDNA) for Fanconi complementation group A, or other clinically certified method of complementation group analysis - Bone marrow analysis demonstrating normal cytogenetics, and no more than 5% of cells with a single clonal abnormality by fluorescence in situ hybridization (FISH) for myelodysplastic syndrome (MDS) panel within 3 months of stem cell collection - Signed informed consent by the patient or legally authorized representative - Absolute neutrophil count >= 0.5 x 10^9/L - Hemoglobin >= 8 g/dL - Platelet count >= 20 x 10^9/L and able to achieve a platelet count of >= 50 x 10^9/L with transfusion support - Adequate hepatic function with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) - Adequate renal function with creatinine (Cre) =< 1.5; if greater, then glomerular filtration rate (GFR) > 60 mL/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease equation - Adequate pulmonary function with corrected diffusion capacity of carbon monoxide (DLCO) > 50% in those for whom this study can be performed - For subjects < 17 years of age, Modified Lansky Play-Performance Score of >= 70%; for subjects 17 and older, Karnofsky score of >= 70% Exclusion Criteria: - Non-hematopoietic malignancy where the expected survival is less than 2 years - Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria - Acute myeloid leukemia as defined by WHO criteria - Pregnancy or lactation; females of childbearing potential and males who are admitted to the study will be advised that the study procedures and study drugs may be teratogenic, and they will be required to take adequate measures to prevent conception for the duration of the study - Concurrent enrollment in any other study using an investigational drug - Physical or emotional status that would prevent informed consent, protocol compliance, or adequate follow-up - Patients for whom an human leukocyte antigen (HLA) matched sibling donor bone marrow transplant is being actively pursued will not be eligible for study until it is determined that no sibling donor is available or that a stem cell transplant is not feasible during the time the patient might be on study - No patient will be included in this study as an alternative to a clinically indicated HLA matched sibling donor stem cell transplant - If an HLA matched sibling donor is identified, but stem cell or marrow collection is not feasible (e.g., donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo a donation procedure because of ill health), a patient may be included in the study at the discretion of the investigators - Significant associated diseases including documented human immunodeficiency virus (HIV) infection, uncontrolled hypertension (diastolic blood pressures > 95%ile for age), unstable angina, congestive heart failure (> New York [NY] class II), poorly controlled diabetes (hemoglobin A1c [Hgb A1c] > 7%), coronary angioplasty within 6 months, myocardial infarction within the last 6 months, or uncontrolled atrial or ventricular cardiac arrhythmia, abnormal coagulation, persistent abnormal urinalysis reflecting intrinsic renal disease - Active ongoing viral, bacterial, or fungal infection

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bone Marrow Aspiration
Undergo bone marrow harvest
Biological:
Filgrastim
Given SC
Genetically Engineered Hematopoietic Stem Progenitor Cells
Undergo infusion of genetically modified hematopoietic progenitor cell therapy
Other:
Laboratory Biomarker Analysis
Correlative studies
Procedure:
Leukapheresis
Undergo leukapheresis
Drug:
Methylprednisolone
Given IV
Plerixafor
Given SC
Prednisone
Given PO

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (3)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center National Heart, Lung, and Blood Institute (NHLBI), Rocket Pharma Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity of gene transfer Adverse events will be graded by Common Terminology Criteria for Adverse Events (CTCAE), version 4. Up to 15 years
Primary Hematological and non-hematological organ toxicity Adverse events will be graded by CTCAE, version 4. Up to 15 years
Primary Development of insertional mutagenesis or hematologic malignancy Adverse events will be graded by CTCAE, version 4. Up to 15 years
Primary Development of replication competent lentivirus Adverse events will be graded by CTCAE, version 4. Up to 15 years
Secondary Efficacy of G-CSF and plerixafor mobilization in Fanconi anemia (FA) patients Up to 6 days
Secondary Efficacy of lineage depletion of bone marrow or mobilized cell product Up to 15 years
Secondary Transduction efficiency After completion of lentiviral transduction, the percent gene modified cells will be determined by molecular studies. Day 0
Secondary Detectable levels of transduced cells in blood and marrow Blood and bone marrow samples will be assayed by real-time quantitative polymerase chain reaction. Up to 1 year
Secondary Improved blood counts Complete blood counts will be monitored, initially weekly, then monthly during the first year, then quarterly during the 2nd year after infusion. Up to 15 years
Secondary Demonstrable functional expression by growth of recipient cells in mitomycin C Blood and bone marrow cells will be assayed for viability of cultured cells and hematopoietic colonies in the presence of the chemotherapy drug and deoxyribonucleic acid crosslinking agent, mitomycin C. 3 months
See also
  Status Clinical Trial Phase
Completed NCT02931071 - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1 Phase 2
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT01146210 - Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia N/A
Completed NCT01082133 - Multicenter Transplant Study for Fanconi Anemia Phase 2
Completed NCT00965666 - Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia Early Phase 1
Terminated NCT00290628 - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer N/A
Recruiting NCT00027274 - Cancer in Inherited Bone Marrow Failure Syndromes
Terminated NCT01001598 - Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita Phase 1/Phase 2
Recruiting NCT03206086 - Eltrombopag for People With Fanconi Anemia Phase 2
Recruiting NCT03579875 - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Phase 2
Recruiting NCT05598515 - Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia N/A
Active, not recruiting NCT03476330 - Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia Phase 2
Terminated NCT05910853 - Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
Completed NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT00479115 - Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 Phase 1/Phase 2
Completed NCT00352976 - TBI Dose De-escalation for Fanconi Anemia Phase 2/Phase 3
Terminated NCT03600909 - A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia Phase 2